Icatibant: all 24 studies that test it
Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.
- A Study of Icatibant (TAK-667) in Japanese Children and Teenagers With Acute Attacks of Hereditary AngioedemaCompletedNCT04654351Phase 3Results posted
- Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2CompletedNCT04113109Phase 4Results posted
- A Study of Icatibant for Acute Attacks of Hereditary Angioedema in Japanese ParticipantsCompletedNCT03888755Phase 3Results posted
- Mitochondria and Chronic Kidney DiseaseCompletedNCT03177798Phase 2Results posted
- Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese VolunteersCompletedNCT02045264Phase 1Results posted
- Blinded Safety & Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Induced AngioedemaCompletedNCT01919801Phase 3Results posted
- Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated AngioedemaTerminatedNCT01574248Phase 4Results posted
- Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAECompletedNCT01457430Phase 4Results posted
- A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary AngioedemaCompletedNCT01386658Phase 3Results posted
- EASSI - Evaluation of the Safety of Self-Administration With IcatibantCompletedNCT00997204Phase 3Results posted
- A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)CompletedNCT00912093Phase 3Results posted
- Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema (HAE)CompletedNCT00500656Phase 3Results posted
- Bradykinin Receptor Antagonism During Cardiopulmonary BypassCompletedNCT00223704Phase 2/3Results posted
- Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary AngioedemaCompletedNCT00097695Phase 3Results posted
- A Study to Evaluate the Safety and Efficacy of Icatibant in Patients With Bradykinin Induced AngioedemaCompletedNCT07290855Phase 4
- Prevention of Intradialytic Hypotension by Inhibiting Bradykinin B2 ReceptorActive, not recruitingNCT05834777Phase 3
- Evaluation of the Effects of Bradykinin Antagonists on Pulmonary Manifestations of COVID-19 Infections (AntagoBrad-Cov Study).CompletedNCT05010876Phase 2
- Investigating the Efficacy and Safety ICATIBANT For The Treatment of Patients With SARS-CoV-2 (COVID-19) InfectionCompletedNCT04978051Phase 2
- I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill PatientsActive, not recruitingNCT04488081Phase 2
- Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2WithdrawnNCT03005184Phase 2
- The Effect of Ischaemic-Reperfusion and Remote Ischaemic Preconditioning in Man - A Bradykinin Dependent PathwayCompletedNCT00965393Not applicable
- The Effect of Ischaemic-Reperfusion in Man - A Bradykinin Dependent PathwayCompletedNCT00965120Not applicable
- Bradykinin Receptor Blocker in ACE Inhibitor-associated AngioedemaTerminatedNCT00517582Phase 1
- Efficacy and Safety Study of Intra-articular Multiple Doses of Icatibant in Patients With Painful Knee OsteoarthritisCompletedNCT00303056Phase 2